The Bladder Cancer Company

About Us

Our Values

Our History

Bladder cancer challenge

Board of directors

Executive Leadership

Leadership

Our Company

Photocure Technology

Our products

Research support

Innovation & Products

News

Addressing inequality

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Our Impact

Why Partner with Photocure

Our Partners

Partners

Photocure culture

Working at Photocure

Careers

Contact

Events & Presentations

Financials

Shareholder information

FAQs

Investors hub

Investors

Press & Media

Privacy Policy

Terms of use

cevira

<p class="spacer"><br></p>
<h1>Shareholders</h1>
<p class="spacer"><br></p>

thumbnail_ShareHolderInfo@2x.png

ESG report

European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care

Medical congresses & events

Medical Information

Partnership News & Expansion

Photocure to Participate in the 23[rd] Annual Needham Virtual Healthcare Conference

Investor conferences

EAU 2024: Photocure Partner Asieris to present the Drug and Equipment Performance Results from the Chinese Phase III Clinical Study of Hexvix in Combination with HD 4K Blue Light Cystoscopy equipment

New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Canadian Health Authorities approve updated and expanded label for Cysview

Product Announcements

Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting

Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO

Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

Photocure ASA: Results for the fourth quarter of 2023

Financial Investment & Stock

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence

Patient Registries

Real World Evidence

Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024

Photocure ASA – Share option grant

Photocure Partner Asieris to present unpublished clinical trial and real-world data on Hexvix in China at ASCO GU 2024

SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="nofollow noopener noreferrer">privacy page</a>.</p>

agree

Shareholders

Investor news

E-mail: info@photocure.no

E-mail: info@photocure.com

E-mail: kontakt@photocure.com